Celiac Research Helped Make a $2.2 Billion Deal. What Does That Mean for Us?
I want a treatment. I also want us to understand what’s behind the headline.
So when a company commits approximately $2.2 billion to acquire the business behind an experimental drug being studied for celiac disease, I pay attention.
That is a lot of money attached to something many of us have spent years hoping for.
But what did that investment actually buy? And how much of the decision was about celiac?
Celiac helped make the case
On July 27, 2026, argenx announced an agreement to acquire Forte Biosciences for approximately $2.2 billion in equity value. Forte’s lead drug candidate was FB102, an experimental antibody targeting CD122.
Argenx specifically identified earlier Phase 1b results in celiac disease and vitiligo as key drivers of its decision to move from a strategic investment to an acquisition.
That means celiac was part of the evidence supporting the deal. We do not have to guess whether our disease mattered. The company said it did.
The timing is worth understanding, too. The acquisition agreement came before the encouraging Phase 2 celiac results announced on October 8. Argenx was investing on the strength of earlier evidence and what it believed could come next.
Its October 8 announcement reports that the acquisition was completed in August and that the Phase 2 study met its primary endpoint. Argenx now plans to advance FB102 into Phase 3 development.
Those are different milestones: an investment decision, a completed acquisition, and a subsequent clinical result.
One drug, several opportunities
FB102 is being investigated for more than celiac disease. Argenx also identifies vitiligo and alopecia areata among its potential uses.
The company calls this a “pipeline-in-a-product.” In ordinary language, that means one drug could potentially support several treatment programs.
Each disease still requires its own evidence. A result in the intestine does not automatically prove a benefit in skin or hair follicles. But several possible uses give a company more opportunities to develop a medicine and eventually generate revenue.
This broader strategy is not exclusive to FB102. Teva’s September announcement about TEV’408 also connects its celiac and vitiligo results to potential across multiple diseases.
The drugs target related biology through different approaches. As I explained when discussing TEV’408 and the questions its results raise, TEV’408 targets IL-15 directly. FB102 targets CD122, a component shared by the IL-15 and IL-2 receptors.
We will get into why those pathways interest researchers across different diseases on Friday. For today, the business point is that the investment covers a broader opportunity than celiac alone.
Millions of patients do not mean millions of customers
Celiac affects millions of people. But a drug company cannot assume that everyone with the disease will take its medicine.
Many people remain undiagnosed. Among those diagnosed, the potential population narrows further with the approved indication, eligibility, willingness, safety, treatment burden, cost, and insurance coverage.
A person who wants protection from accidental exposure might make a different decision from someone offered regular infusions with uncertain long-term benefits.
We do not yet know what an approved FB102 treatment would look like or who would qualify. We therefore cannot turn disease prevalence into a reliable sales forecast.
A smaller patient population can still support a commercially valuable medicine. Price, treatment duration, international markets, and competing therapies all matter. The point is that the market is more complicated than counting everyone who has celiac.
Why this investment matters to us
My interpretation is that several potential indications can strengthen the business case for investing in a drug. They offer more possible routes to a return on that investment.
They do not guarantee that the celiac program will continue regardless of its results. Companies still choose where to spend their resources. A disappointing result in one disease might leave other programs viable; a significant safety problem could have wider consequences.
And the acquisition price is not the budget for a celiac trial. It is the price of acquiring a company and the broader opportunity represented by its drug candidate.
Still, I find it encouraging that celiac evidence helped support a decision of this size. Research involving our community contributed to something a company considered worth pursuing.
A valuable investment still has to become a useful treatment
The October 8 FB102 announcement reports positive Phase 2 findings, but detailed results are still expected at a medical meeting. An acquisition and encouraging topline results cannot answer every patient question.
How much protection does it provide? How durable is that protection? What does long-term treatment mean for safety? What would treatment ask of us? And could we actually access it?
These are the kinds of better tools and treatments our community needs. The practical benefit matters alongside the scientific milestone.
I want this investment to lead somewhere useful for us. A treatment that makes daily life safer and less exhausting would mean far more to me than an impressive transaction.
For now, we can recognize something meaningful: celiac research helped make the case for a multibillion-dollar acquisition. We can be hopeful about that and still ask what comes next.
Tomorrow, we will look at what a gluten challenge can demonstrate—and what those results still leave unanswered about everyday life.
What would you need to know before considering a celiac treatment?
If these explanations help you understand the news and ask better questions, follow Fat Celiac and share this with someone waiting for better treatment options.
Think. Understand. Laugh. Live better with celiac disease.
Leave a Reply